Meet the Passages Malibu Staff: Chris Prentiss
Meet the Passages Malibu Staff: Chris Prentiss – Chris Prentiss is the co-founder of Passages Malibu and Passages Ventura addiction treatment centers in California. His unique philosophy to treating drug and alcohol addiction is also outlined in his book, “The Alcoholism & Addiction Cure.” Prentiss, along with his son, co-founder and CEO Pax Prentiss, have truly revolutionized addiction treatment by believing that addiction is not a disease. Instead, it’s a symptom of an underlying condition that needs to be discovered and healed. In the wake of Passages Malibu’s 2001 debut (with Passages Ventura following in 2009), many other holistic, non-12 Step treatment centers have tried to copy what we do. But, Passages remains the industry leader in holistic, non-12 Step substance abuse treatment centers. At Passages, we believe in a cure. We believe in you. For more information, please visit www.passagesmalibu.com or call (888) 720-6302.
La Jolla Pharmaceutical Company Adds to Management Team
Filed under: drug addiction treatment centers california
SAN DIEGO, CA — (Marketwire) — 01/14/13 — La Jolla Pharmaceutical Company (OTCQB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics that target galectin-3, announced today that it has recently made two additions to its …
Read more on Equities.com
Rehab program hosting drug abuse symposium
Filed under: drug addiction treatment centers california
Police, fire and community leaders, along with recovering addicts, will speak about the problem of substance abuse on the local level. Experts will talk about where the drugs are coming from, what they look like, where they are hidden and the signs of …
Read more on Simi Valley Acorn
Reviva Pharmaceuticals Announces Completion of Patient Enrollment in Phase …
Filed under: drug addiction treatment centers california
SAN JOSE, Calif., Jan 14, 2013 (BUSINESS WIRE) — Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of …
Read more on MarketWatch (press release)